secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001193125-23-070166
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech reports 2022 net loss of $71.5M; cash runway through Q3 2024
-----------------------------------------------------------------------

- Net loss $71.5M for 2022 vs $67.9M for 2021; Q4 net loss $20.1M vs $21.3M.
- R&D expenses $47.0M (+56% YoY) driven by Phase 3 trial execution; G&A $24.4M (+120%).
- Cash and equivalents $142.6M at Dec 31, 2022, down from $211.5M; expects runway through Q3 2024.
- Phase 3 advanced melanoma trial (IOB-013) targets 75% enrollment by mid-2023; interim ORR analysis could enable accelerated BLA.
- Appointed Amy Sullivan CFO (Oct 2022) and Devin Smith GC (Jan 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/0001193125-23-070166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/d464597d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-070166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer